The Life Sciences Innovative Manufacturing Fund (LSIMF) is a capital grants fund which aims to build resilience for future health emergencies and capitalise on the UK’s world-leading research and development capabilities.
The fund will enhance and accelerate affordable access to mature, new and emerging Life Sciences products for both pandemic and non-pandemic scenarios.
LSIMF will provide up to £520 million in capital grants for investment in the manufacture of human medicines and medical technology (including diagnostics, and MedTech products).
This is a new fund from previous UK Government Life Sciences manufacturing funds.
LSIMF is open to all eligible companies, including previous manufacturing grant recipients, as long as the application is for a different project.
